AssetMark Inc
ARQT icon

AssetMark Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

AssetMark Inc’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.8K Buy
2,012
+495
+33% +$11.5K ﹤0.01% 1816
2026
Q1 		$35.7K Hold
1,517
– – ﹤0.01% 1859
2025
Q4 		$44.1K Sell
1,517
-343
-18% -$8.78K ﹤0.01% 1761
2025
Q3 		$35.1K Hold
1,860
– – ﹤0.01% 1761
2025
Q2 		$26.1K Hold
1,860
– – ﹤0.01% 1740
2025
Q1 		$29.1K Hold
1,860
– – ﹤0.01% 1599
2024
Q4 		$25.9K Hold
1,860
– – ﹤0.01% 1594
2024
Q3 		$17.3K Hold
1,860
– – ﹤0.01% 1526
2024
Q2 		$17.3K Hold
1,860
– – ﹤0.01% 1409
2024
Q1 		$18.4K Hold
1,860
– – ﹤0.01% 1294
2023
Q4 		$6.01K Hold
1,860
– – ﹤0.01% 1434
2023
Q3 		$9.88K Hold
1,860
– – ﹤0.01% 1335
2023
Q2 		$17.7K Buy
1,860
+255
+16% +$2.83K ﹤0.01% 1227
2023
Q1 		$17.7K Buy
1,605
+250
+18% +$3.62K ﹤0.01% 1205
2022
Q4 		$20.1K Buy
1,355
+440
+48% +$7.69K ﹤0.01% 1203
2022
Q3 		$17K Buy
915
+375
+69% +$8.5K ﹤0.01% 1152
2022
Q2 		$12K Buy
+540
New +$11.1K ﹤0.01% 1197

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AssetMark Inc's ARQT Position: Q2 2026 in Review

AssetMark Inc increased its Arcutis Biotherapeutics (ARQT) stake by 33% in Q2 2026, buying an estimated $11.5K and bringing the position to 2,012 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

AssetMark Inc first reported a position in ARQT in Q2 2022 and has held it in 17 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • AssetMark Inc held 2,012 shares of Arcutis Biotherapeutics worth $52.8K as of Q2 2026.
  • AssetMark Inc bought 495 Arcutis Biotherapeutics shares in Q2 2026, an estimated $11.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1816 holding.
  • AssetMark Inc first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.